We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Automated AI-Powered Microscope Accurately Identifies Malaria Parasites in Blood Samples

By LabMedica International staff writers
Posted on 11 Aug 2023

Every year, over 200 million individuals contract malaria, with more than half a million of these cases resulting in fatalities. More...

The World Health Organization advocates for the use of parasite-based diagnosis prior to commencing treatment for the infectious disease caused by Plasmodium parasites. Various diagnostic techniques are available, including conventional light microscopy, rapid diagnostic tests, and PCR. Nevertheless, the established benchmark for malaria diagnosis is manual light microscopy, where a specialist examines blood samples under a microscope to verify the presence of malaria parasites. However, the result accuracy is heavily dependent on the expertise of the microscopist and can be affected by fatigue caused by workloads among the professionals conducting the tests.

Due to the demanding nature of traditional diagnosis and the high workload, an international team of researchers undertook an investigation into the feasibility of employing a novel system that combines an automated scanning microscope with artificial intelligence (AI) for clinical diagnosis. The results indicated that this system identified malaria parasites with almost the same accuracy as experienced microscopists following standard diagnostic procedures. This advancement holds the potential to ease the burden of microscopists and increase the manageable patient caseload.

Researchers at The Hospital for Tropical Diseases at UCLH (London, UK) tested a fully automated malaria diagnostic system comprising both hardware and software components. The automated microscopy platform scans blood samples, and algorithms for malaria detection process the images to detect the presence and quantity of parasites. The researchers analyzed more than 1,200 blood samples from travelers who had returned to the UK from regions where malaria is prevalent. The study evaluated the accuracy of the AI-microscope system in a true clinical setting under ideal conditions.

The researchers compared the results obtained from both manual light microscopy and the AI-microscope system. Manually, 113 samples were identified as having malaria parasites, whereas the AI system accurately detected 99 positive samples, resulting in an 88% accuracy rate. Despite this commendable accuracy rate, the automated system also produced false positives, indicating 122 samples as positive when they were not, potentially leading to unnecessary administration of anti-malarial drugs to patients.

“At an 88% diagnostic accuracy rate relative to microscopists, the AI system identified malaria parasites almost, though not quite, as well as experts,” said Dr. Roxanne Rees-Channer, a researcher at The Hospital for Tropical Diseases at UCLH. “This level of performance in a clinical setting is a major achievement for AI algorithms targeting malaria. It indicates that the system can indeed be a clinically useful tool for malaria diagnosis in appropriate settings.”

Related Links:
UCLH 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.